靶向结核耐药机制的抗结核药物增效剂的研究进展

doi:10.5246/jcps.2024.02.008

中国药学(英文版) ›› 2024, Vol. 33 ›› Issue (2): 89-97.DOI: 10.5246/jcps.2024.02.008

• 【综述】 • 下一篇

靶向结核耐药机制的抗结核药物增效剂的研究进展

杨建慧¹, 王潇², 张金波¹^,^*(), 刘忆霜²^,^*()

^1. 佳木斯大学基础医学院, 黑龙江佳木斯 154007
^2. 中国医学科学院北京协和医学院医药生物技术研究所, 国家新药(微生物)筛选实验室, 北京 100050

收稿日期:2023-10-26 修回日期:2023-11-24 接受日期:2023-12-21 出版日期:2024-03-03 发布日期:2024-03-03
通讯作者: 张金波, 刘忆霜

Advancements in anti-tuberculosis drug potentiators: targeting mechanisms of tuberculosis resistance

Jianhui Yang¹, Xiao Wang², Jinbo Zhang¹^,^*(), Yishuang Liu²^,^*()

¹ School of Basic Medicine, Jiamusi University, Jiamusi 154007, Heilongjiang, China
² National Key Laboratory for Screening New Microbial Drugs, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China

Received:2023-10-26 Revised:2023-11-24 Accepted:2023-12-21 Online:2024-03-03 Published:2024-03-03
Contact: Jinbo Zhang, Yishuang Liu
Supported by:
CAMS Innovation Fund for Medical Sciences (Grant No. CIFMS, 2021-I2M-1-028) and the National Natural Science Foundation of China (Grant No. 81903678).

摘要/Abstract

摘要：

结核病(Tuberculosis, TB)是一个全球性的健康问题, 由于耐多药结核病(multidrug-resistant tuberculosis, MDR-TB)菌株的出现, 抗结核药物出现防治困难。针对耐药机制开发抗结核药物的增效剂可以减少耐药性的出现和缩短治疗时间。本文从靶向细胞壁、外排泵和β-内酰胺酶的增效剂与抗结核药物的联合应用进行综述, 为后续开发活性更好、毒性更小的新型增效剂提供参考。

关键词: 结核病, 耐药菌株, 抗结核药物增效剂

Abstract:

Tuberculosis (TB) constitutes a formidable global health challenge, exacerbated by the rise of multidrug-resistant TB (MDR-TB) strains. The effectiveness of anti-TB drugs has been hindered by this emergence of resistance. To address this, the development of synergistic compounds, informed by drug resistance mechanisms, holds promise for mitigating resistance emergence and shortening treatment durations. This review focuses on the amalgamation of anti-TB drugs with potentiators targeting the cell wall, efflux pump, and β-lactamase. Our aim is to offer insights that guide the future development of novel potentiators with enhanced efficacy and reduced toxicity.

Key words: Tuberculosis, Drug-resistant strains, Anti-tuberculosis drug potentiators

Supporting:

杨建慧, 王潇, 张金波, 刘忆霜. 靶向结核耐药机制的抗结核药物增效剂的研究进展[J]. 中国药学(英文版), 2024, 33(2): 89-97.

Jianhui Yang, Xiao Wang, Jinbo Zhang, Yishuang Liu. Advancements in anti-tuberculosis drug potentiators: targeting mechanisms of tuberculosis resistance[J]. Journal of Chinese Pharmaceutical Sciences, 2024, 33(2): 89-97.

图/表 3

参考文献 30

[1]	World Health Organization. Global Tuberculosis Report 2022. Geneva: World Health Organization, 2022. This article can be found online at https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022.
[2]	Andres, S.; Merker, M.; Heyckendorf, J.; Kalsdorf, B.; Rumetshofer, R.; Indra, A.; Hofmann-Thiel, S.; Hoffmann, H.; Lange, C.; Niemann, S.; Maurer, F.P. Bedaquiline-resistant tuberculosis: dark clouds on the horizon. Am. J. Respir. Crit. Care Med. 2020, 201, 1564–1568.
[3]	Nimmo, C.; Millard, J.; Brien, K.; Moodley, S.; van Dorp, L.; Lutchminarain, K.; Wolf, A.; Grant, A.D.; Balloux, F.; Pym, A.S.; Padayatchi, N.; O'Donnell, M. Bedaquiline resistance in drug-resistant tuberculosis HIV co-infected patients. Eur. Respir. J. 2020, 55, 1902383.
[4]	Polsfuss, S.; Hofmann-Thiel, S.; Merker, M.; Krieger, D.; Niemann, S.; Rüssmann, H.; Schönfeld, N.; Hoffmann, H.; Kranzer, K. Emergence of low-level delamanid and bedaquiline resistance during extremely drug-resistant tuberculosis treatment. Clin. Infect. Dis. 2019, 69, 1229–1231.
[5]	Singh, R.; Dwivedi, S.P.; Gaharwar, U.S.; Meena, R.; Rajamani, P.; Prasad, T. Recent updates on drug resistance in Mycobacterium tuberculosis. J. Appl. Microbiol. 2020, 128, 1547–1567.
[6]	Pushkaran, A.C.; Vinod, V.; Vanuopadath, M.; Nair, S.S.; Nair, S.V.; Vasudevan, A.K.; Biswas, R.; Mohan, C.G. Combination of repurposed drug diosmin with amoxicillin-clavulanic acid causes synergistic inhibition of mycobacterial growth. Sci. Rep. 2019, 9, 6800.
[7]	Nawaz, N.; Wen, S.; Wang, F.H.; Nawaz, S.; Raza, J.; Iftikhar, M.; Usman, M. Lysozyme and its application as antibacterial agent in food industry. Molecules. 2022, 27, 6305.
[8]	Aguilar-Pérez, C.; Gracia, B.; Rodrigues, L.; Vitoria, A.; Cebrián, R.; Deboosère, N.; Song, O.R.; Brodin, P.; Maqueda, M.; Aínsa, J.A. Synergy between circular bacteriocin AS-48 and ethambutol against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2018, 62, e00359–18.
[9]	Song, L.L.; Wu, X.Q. Development of efflux pump inhibitors in antituberculosis therapy. Int. J. Antimicrob. Agents. 2016, 47, 421–429.
[10]	Pule, C.M.; Sampson, S.L.; Warren, R.M.; Black, P.A.; van Helden, P.D.; Victor, T.C.; Louw, G.E. Efflux pump inhibitors: targeting mycobacterial efflux systems to enhance TB therapy. J. Antimicrob. Chemother. 2016, 71, 17–26.
[11]	Chen, C.; Gardete, S.; Jansen, R.S.; Shetty, A.; Dick, T.; Rhee, K.Y.; Dartois, V. Verapamil targets membrane energetics in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2018, 62, e02107–e02117.
[12]	Adams, K.N.; Szumowski, J.D.; Ramakrishnan, L. Verapamil, and its metabolite norverapamil, inhibit macrophage-induced, bacterial efflux pump-mediated tolerance to multiple anti-tubercular drugs. J. Infect. Dis. 2014, 210, 456–466.
[13]	de Souza, J.V.P.; Murase, L.S.; Caleffi-Ferracioli, K.R.; Palomo, C.T.; de Lima Scodro, R.B.; Siqueira, V.L.D.; Pavan, F.R.; Cardoso, R.F. Isoniazid and verapamil modulatory activity and efflux pump gene expression in Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis. 2020, 24, 591–596.
[14]	Valıyeva, G.; Durupınar, B.; Coban, A.Y. Efflux pump effects on Mycobacterium tuberculosis drug resistance. J. Chemother. 2023, 35, 601–609.
[15]	Singh, M.; Jadaun, G.P.S.; Ramdas, Srivastava, K.; Chauhan, V.; Mishra, R.; Gupta, K.; Nair, S.; Chauhan, D.S.; Sharma, V.D.; Venkatesan, K.; Katoch, V.M. Effect of efflux pump inhibitors on drug susceptibility of ofloxacin resistant Mycobacterium tuberculosis isolates. Indian J. Med. Res. 2011, 133, 535–540.
[16]	Jain, A.; Jaiswal, I.; Verma, S.K.; Singh, P.; Kant, S.; Singh, M. Effect of efflux pump inhibitors on the susceptibility of Mycobacterium tuberculosis to isoniazid. Lung India. 2017, 34, 499–505.
[17]	Hegeto, L.A.; Caleffi-Ferracioli, K.R.; Nakamura-Vasconcelos, S.S.; de Almeida, A.L.; Baldin, V.P.; Nakamura, C.V.; Siqueira, V.L.D.; Scodro, R.B.L.; Cardoso, R.F. In vitro combinatory activity of piperine and anti-tuberculosis drugs in Mycobacterium tuberculosis. Tuberculosis. 2018, 111, 35–40.
[18]	Lentz, F.; Reiling, N.; Spengler, G.; Kincses, A.; Csonka, A.; Molnár, J.; Hilgeroth, A. Dually acting nonclassical 1,4-dihydropyridines promote the anti-tuberculosis (Tb) activities of clofazimine. Molecules. 2019, 24, 2873.
[19]	Halicki, P.C.B.; Vianna, J.S.; Zanatta, N.; de Andrade, V.P.; de Oliveira, M.; Mateus, M.; da Silva, M.V.; Rodrigues, V.; Ramos, D.F.; Almeida da Silva, P.E. 2, 2, 2-trifluoro-1-(1, 4, 5, 6-tetrahydropyridin-3-yl)ethanone derivative as efflux pump inhibitor in Mycobacterium tuberculosis. Bioorg. Med. Chem. Lett. 2021, 42, 128088.
[20]	Kumar, M.; Singh, K.; Naran, K.; Hamzabegovic, F.; Hoft, D.F.; Warner, D.F.; Ruminski, P.; Abate, G.; Chibale, K. Design, synthesis, and evaluation of novel hybrid efflux pump inhibitors for use against Mycobacterium tuberculosis. ACS Infect. Dis. 2016, 2, 714–725.
[21]	Xiao, C.L. Establishment and application of the screening model of the Mycobacterium tuberculosis β-lactamase BlaC inhibitors. J. Chin. Pharm. Sci. 2016, 25, 189–195.
[22]	Flores Anthony, R.; Parsons Linda, M.; Pavelka Martin, S. Genetic analysis of the beta-lactamases of Mycobacterium tuberculosis and Mycobacterium smegmatis and susceptibility to beta-lactam antibiotics. Microbiol. Read. Engl. 2005, 151, 521–532.
[23]	Hugonnet, J.E.; Tremblay, L.W.; Boshoff, H.I.; Barry, C.E.; Blanchard, J.S. Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis. Science. 2009, 323, 1215–1218.
[24]	Han, J.X; Liu, Y.S.; Xiao, C.L. Research progress of β-lactamase inhibitors. Chin. J. Antibio. 2019, 44, 647–653.
[25]	Payen, M.C.; Muylle, I.; Vandenberg, O.; Mathys, V.; Delforge, M.; Van den Wijngaert, S.; Clumeck, N.; De Wit, S. Meropenem-clavulanate for drug-resistant tuberculosis: a follow-up of relapse-free cases. Int. J. Tuberc. Lung Dis. 2018, 22, 34–39.
[26]	Li, F.; Wang, R.B.; Xiao, T.Y.; Liu, H.; Jiang, Y.; Wan, K.L. Sensitivity analysis of Mycobacterium tuberculosis to β-lactamase inhibitors with tebipenem. Dis. Surveil. 2018, 33, 241–245.
[27]	Shi, J.; Zheng, D.W.; Ma, X.G.; Su, R.Y.; Zhu, Y.K.; Wang, S.H.; Chang, W.J.; Sun, G.Q.; Sun, D.Y. In vitro activity of β-lactamase inhibitors avibanvctam and relebactam in combination with β-lactams against multidrug-resistant Mycobacterium tuberculosis and mutations of resistance genes. Chin. J. Tuberc. Respir. Dis. 2023, 46, 797–805.
[28]	Yan, F.; He, S.G.; Han, X.Y.; Wang, J.Y.; Tian, X.G.; Wang, C.; James, T.D.; Cui, J.N.; Ma, X.C.; Feng, L. High-throughput fluorescent screening of β-lactamase inhibitors to improve antibiotic treatment strategies for tuberculosis. Biosens. Bioelectron. 2022, 216, 114606.
[29]	Jeon, A.B.; Obregón-Henao, A.; Ackart, D.F.; Podell, B.K.; Belardinelli, J.M.; Jackson, M.; Nguyen, T.V.; Blackledge, M.S.; Melander, R.J.; Melander, C.; Johnson, B.K.; Abramovitch, R.B.; Basaraba, R.J. 2-Aminoimidazoles potentiate β-lactam antimicrobial activity against Mycobacterium tuberculosis by reducing β-lactamase secretion and increasing cell envelope permeability. PLoS One. 2017, 12, e0180925.
[30]	Xiao, S.Q.; Guo, H.D.; Weiner, W.S.; Maddox, C.; Mao, C.H.; Gunosewoyo, H.; Pelly, S.; White, E.L.; Rasmussen, L.; Schoenen, F.J.; Aubé, J.; Bishai, W.R.; Lun, S.C. Revisiting the β-lactams for tuberculosis therapy with a compound-compound synthetic lethality approach. Antimicrob. Agents Chemother. 2019, 63, e01319–19.

靶向结核耐药机制的抗结核药物增效剂的研究进展

Advancements in anti-tuberculosis drug potentiators: targeting mechanisms of tuberculosis resistance

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 3

参考文献 30

相关文章 1

编辑推荐

Metrics

本文评价